Abstract | OBJECTIVE: METHODS: RESULTS: MeV-SCD was demonstrated to infect, replicate in and effectively lyse not only human ovarian cancer cell lines, but also primary tumor cells (albeit at lower efficiencies) that were derived from malignant ascites of ovarian cancer patients. Addition of the prodrug 5-FC significantly enhanced cell killing. Importantly, precision-cut tumor slices of human ovarian cancer patient specimens were efficiently infected with MeV-SCD. The prodrug-converting enzyme SCD was expressed by all infected tumor slices, thereby ensuring provision of the suicide gene arming function in patient-derived materials. CONCLUSIONS: With respect to safety and therapeutic impact, arming of oncolytic measles vaccine virus warrants further clinical investigation for ovarian cancer treatment.
|
Authors | A D Hartkopf, S Bossow, J Lampe, M Zimmermann, F-A Taran, D Wallwiener, T Fehm, M Bitzer, U M Lauer |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 130
Issue 2
Pg. 362-8
(Aug 2013)
ISSN: 1095-6859 [Electronic] United States |
PMID | 23676551
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
- Measles Vaccine
- Flucytosine
- Pentosyltransferases
- uracil phosphoribosyltransferase
- Cytosine Deaminase
|
Topics |
- Cell Line, Tumor
- Cytosine Deaminase
(genetics)
- Female
- Flucytosine
(pharmacology)
- Genetic Therapy
- Humans
- Measles Vaccine
- Measles virus
(genetics)
- Oncolytic Virotherapy
(methods)
- Ovarian Neoplasms
(therapy)
- Pentosyltransferases
(genetics)
- Saccharomyces cerevisiae
(enzymology)
|